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Abstract: 
Introduction:  Perinatal or Mother-to-Child transmission (MTCT) of hepatitis B virus (HBV) 
remains the major risk factor for chronic HBV infection worldwide.  In addition to hepatitis B 
immune globulin (HBIG) and vaccination, oral antiviral therapies in highly viremic mothers can 
further decrease MTCT of HBV.  We conducted a systematic review and meta-analysis to 
synthesize the evidence on the efficacy and maternal and fetal safety of antiviral therapy during 
pregnancy.  Methods: A protocol was developed by American Association for the Study of 
Liver Diseases (AASLD) guideline writing committee. We searched multiple databases for 
controlled studies that enrolled pregnant women with chronic HBV infection treated with 
antiviral therapy. Outcomes of interest were reduction of MTCT and adverse outcomes to 
mothers and newborns. Study selection and data extraction were done by pairs of independent 
reviewers. Results: We included 26 studies that enrolled 3622 pregnant women.  Antiviral 
therapy reduced MTCT, as defined by infant hepatitis B surface antigen (HBsAg) seropositivity 
(RR 0.3 (0.2 - 0.4) and infant HBV DNA seropositivity (RR 0.3, (0.2 - 0.5) at 6-12 months.  No 
significant difference was found in the congenital malformation rate, prematurity rate and 
APGAR scores. Compared to control, lamivudine or telbivudine improved maternal HBV DNA 
suppression at delivery and during 4-8 weeks postpartum follow up. Tenofovir showed 
improvement in HBV DNA suppression at delivery.  No significant differences were found in 
postpartum hemorrhage, cesarean section and elevated creatinine kinase rates. Conclusions:  
Antiviral therapy improves HBV suppression and reduces MTCT in women with chronic HBV 
infection with high viral load compared to the use of HBIG and vaccination alone. The use of 
telbivudine, lamivudine and tenofovir appear to be safe in pregnancy with no increased adverse 
maternal or fetal outcome. 
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Introduction: 
Chronic hepatitis B virus (HBV) infection remains an important global health problem.  Up to 
600,000 of the approximately 240 million carriers worldwide die annually due to chronic 
hepatitis B (CHB)-related disease (1).  Perinatal or mother-to-child transmission (MTCT) is the 
most common form of transmission of HBV in many high prevalence areas (2, 3) and may occur 
in up to 90% of mothers who are hepatitis B surface antigen (HBsAg) and hepatitis B e antigen 
(HBeAg) positive in the absence of prophylaxis (4). This high rate of transmission may be 
partially due to the high proportion of mothers with active replication and HBeAg positivity 
during reproductive years (5-8) particularly in Asian countries and regions of the world where 
HBV genotype C is found (9) as MTCT is associated with high maternal viral load (HBV DNA 
> 10
6
 IU/ml) (10-13). Universal prenatal testing of women is therefore recommended, as are 
hepatitis B vaccination and hepatitis B immunoglobulin (HBIG) administration starting at birth 
to prevent transmission to the newborn.   
Women in their child-bearing years with CHB may need antiviral therapy independent of its 
impact on MTCT if they have immune active HBV infection. Accordingly, data on the safety of 
antivirals during pregnancy, and especially their impact on potential teratogenicity, are of 
paramount importance when counseling pregnant patients with CHB on risks and benefits to 
their offspring.    
Antiviral therapies for CHB have advanced markedly in the last decade.  The newer, more 
potent, nucleos(t)ide analogues durably suppress HBV viremia in most patients. Evolving data 
for CHB patients show low (0-1%) rates of viral resistance and breakthrough after up to 6 years 
Page 5 of 43
Hepatology
Hepatology












July 20, 2015 
of entecavir or tenofovir monotherapy (14, 15). The benefits of long-term virus suppression 
include slowing of liver disease progression and reversal of fibrosis and cirrhosis (16-18).  
Although no HBV therapies are currently approved for use in pregnancy, women being treated 
for CHB may become pregnant. Moreover, pregnant women in the immune tolerant phase of 
CHB with high HBV DNA levels (>10
7
 IU/mL) may want to be considered for antiviral therapy 
to reduce HBV DNA level and decrease the risk of MTCT that can occur despite neonatal 
immunoprophylaxis (10)
 
(19).  Safety data on the use of anti-HBV therapies are largely derived 
from HIV positive mothers studied in the Anti-retroviral Pregnancy Registry, which do not 
report any adverse impact of lamivudine or tenofovir use(20).  However, the use of antiviral 
therapies in pregnancy is controversial and knowledge about the harm and benefit ratio is not 
widely disseminated among hepatologists and other providers including those specializing in 
women’s health. Therefore, the American Association for the Study of Liver Diseases (AASLD) 
made this issue a priority for clinical practice guideline development and evidence synthesis. We 
performed a systematic review and meta-analysis to compare the effect of oral HBV therapy 
(lamivudine, entecavir, telbivudine or tenofovir) on MTCT prevention, HBV DNA suppression, 
and on maternal and fetal safety including major birth defect rates. 
Methods: 
This systematic review follows a protocol developed by a guideline writing group from the 
AASLD and is reported according to the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) statement (21). 
Eligibility Criteria: 
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We included controlled or comparative studies that enrolled pregnant women diagnosed with 
chronic HBV infection (characterized by the presence of HBsAg for more than 6 months), who 
received antiviral therapy and reported the outcomes of interest, including prevention of MTCT 
of HBV, clinical efficacy, and adverse outcomes from antiviral therapy to both mothers and 
newborns. Both English and non-English language studies were included. We excluded studies 
that enrolled infants who did not receive immunization during the first week postpartum; studies 
of patients co-infected with hepatitis C, D or human immunodeficiency viruses (HIV); patients 
receiving steroids, chemo/immunotherapy, liver transplant recipients and patients undergoing 
hemodialysis; and uncontrolled studies or studies published as abstracts only. 
Search strategy: 
A comprehensive search of Medline In-Process & Other Non-Indexed Citations, Ovid 
MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, and Scopus 
was conducted from early 1988 to September 11
th
 2014. The search strategy was designed and 
conducted by an experienced librarian (LJP) with input from the principal investigator. 
Controlled vocabulary supplemented with keywords was used to search for studies of antivirals 
for hepatitis B in pregnancy. Details of the search strategy are available in supplemental Table 1. 
A manual search of bibliographies of the included studies and relevant systematic reviews was 
conducted. Content experts from AASLD were also queried for potential references. 
Study selection: 
Two independent reviewers screened titles and abstracts for potential eligibility in duplicate 
using an online reference management system (DistillerSR, Evidence Partners, Inc.). Included 
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abstracts were then reviewed in full text following the same procedure. Disagreements were 
reconciled by consensus or by a third reviewer.  
Data Extraction: 
For each study, data extraction was done in duplicate using a standardized, pretested form. A 
third reviewer compared data and resolved inconsistencies by referring to the full text of the 
articles. We extracted the following data from each study: study characteristics, patient baseline 
characteristics, intervention details and outcomes of interest. 
Outcomes: 
We were interested in the following outcomes: infant outcomes including the risk of vertical 
transmission, defined by HBsAg seropositivity at 6-12 months or HBV DNA positivity at 6-12 
months, APGAR score (1 minute), prematurity rate and congenital malformation rate. Maternal 
outcomes included HBV DNA suppression, alanine aminotransferase (ALT) normalization, 
HBeAg loss, HBeAg seroconversion, cesarean section rate (CS), postpartum hemorrhage rate 
and elevated creatine kinase. 
Risk of bias assessment: 
Two reviewers independently assessed the risk of bias (i.e., systematic error) using the Cochrane 
Risk of Bias assessment tool and the Newcastle-Ottawa Scale (NOS) for randomized controlled 
trials (RCTs) and observational studies, respectively. The quality of evidence (i.e., certainty in 
the estimates) was evaluated using the Grading of Recommendations Assessment, Development, 
and Evaluation (GRADE) approach. Criteria used to evaluate quality of evidence were risk of 
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bias, indirectness (surrogate outcomes), imprecision (wide confidence intervals), inconsistency 
(heterogeneity) and publication bias (22). 
Statistical analysis: 
For dichotomized outcomes, we calculated the risk ratio and 95% confidence intervals using 
binomial distribution. We then pooled the log transformed risk ratios using the DerSimonian and 
Laird random-effect models and estimated heterogeneity using the Mantel-Haenszel model. For 
continuous outcomes, we calculated the weighted difference in means between the baseline and 
the longest duration of follow-up for each study and pooled effect size using the DerSimonian 
and Laird random-effect model. To measure the overall heterogeneity across the included 
studies, we used the I² statistic, where I² >50% suggests high heterogeneity. All statistical 
analyses were conducted using STATA, version 13 (StataCorp LP, College Station, TX). We 
planned to explore the impact of publication bias using the Egger regression asymmetry test and 
by constructing funnel plots if a sufficient number of studies (>20) per outcome was available 
and heterogeneity was low (23). 
Results: 
The initial search resulted in 734 citations and 3 systematic reviews (24-26) that included the 
China Biological Medicine Database and summarized additional studies published in Chinese. 
We eventually included 26 studies. The average weighted Kappa for study selection was 0.82. 
The study selection process and reasons for exclusions are depicted in figure 1.  
Characteristics of the included studies: 
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Twenty six studies that enrolled a total of 3622 pregnant women were included in the analysis, 
10 studies (27-36) were RCTs and 16 studies (37-52) were non randomized studies. Most of the 





 trimester with an average baseline HBV DNA level of 7.63 log10 IU/mL and 
average baseline ALT level of 37.7 U/L. In these studies, all infants received hepatitis B vaccine 
at birth. Table 1 summarizes the characteristics of the studies. 
Among included studies, 11 studies compared lamivudine vs control; 9 studies (27, 36, 37, 43-
45, 49, 50, 52) compared telbivudine vs control; 2 studies (37) (52) compared lamivudine vs 
telbivudine; 3 studies (38, 39) (51) compared tenofovir vs control and another study (38) 
compared tenofovir vs lamivudine. 
Five RCTs (28-30, 32, 35) were considered to have low risk of bias while 5 studies (27, 31, 33, 
34, 36) were considered to high risk of bias due to unclear/unreported methods of randomization, 
allocation concealment, blinding, or incomplete outcome data reporting.  For non-randomized 
studies, the overall methodological quality and features were adequate/ appropriate as 60% of the 
studies reported adequate patient selection methods, comparable study groups, and adequate 
outcome measures and follow up data. Tables 2 and 3 include detailed description of the risk of 
bias assessment. 
Infant outcomes: 
Use of any antiviral therapy compared to control in pregnant women reduced the likelihood of 
MTCT as defined by infant HBsAg seropositivity (8 RCTs, RR 0.3 (95% CI, 0.2 - 0.4) 
I
2
=63.9%) or infant HBV DNA positivity (5 RCTs, RR 0.3 (95% CI, 0.2 - 0.5) I
2
= 47.2%) at 6-
12 months (Figure 2). Use of any antiviral compared to control reduced the risk of infant HBsAg 
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seropositivity and HBV DNA positivity by 13.4% and 18.7% respectively. The quality of 
evidence was moderate to low, rated down due to risk of bias. This significant reduction 
persisted when comparing individual drugs vs control at 6-12 months after birth. Lamivudine 
(Figure 3) reduced infant HBsAg seropositivity by 11.7% (5 RCTs, RR 0.3 (95% CI, 0.2 - 0.6) 
I
2
= 42.4%) and infant HBV DNA positivity by 21.2% (3 RCTs, RR 0.3 (95% CI, 0.2 to 0.6) 
I
2
=47.9%). Telbivudine also reduced infant HBsAg seropositivity by 15.8% (4 RCTs, RR 0.2 
(95% CI, 0.1 - 0.5) I
2
= 0%) and infant HBV DNA positivity by 16.2% (2 RCTs, RR 0.1 (95% 
CI, 0.03 to 0.6) I
2
= 62.4%) compared to the control group (Figure 4). 
In 3 non-randomized studies (38, 39, 51), tenofovir vs control (Figure 5) reduce infant HBsAg 
seropositivity by 15.8% at 6-12 months follow up (RR 0.2 (95% CI, 0.1 to 0.7) I
2
= 0%).  
Compared to lamivudine, telbivudine (1 study, RR 1 (95% CI, 0.7 to 1.5) and tenofovir (1 study, 
RR 2.93 (95% CI, 0.12 to 70.08) showed no statistically significant reduction in infant HBsAg 
seropositivity at 6-12 months. 
When comparing any antiviral therapy vs. control for fetal harms, no statistically significant 
difference was found in any of the non RCTs reporting on congenital malformation rate, 
prematurity rate and APGAR scores (Figure 6). The quality of the evidence of infant outcomes 
was moderate to low, down rated due to risk of bias and imprecision.  
Maternal outcomes: 
Compared to control, lamivudine improved maternal HBV DNA suppression before delivery (1 
cohort, RR 57.1, 95% CI, 3.5 - 921.4) and during 4-8 weeks postpartum follow up (2 cohorts, RR 
70.9, (95% CI, 8.5 - 590) I
2
=12.2%) . No significant difference was found in maternal ALT 
normalization.  
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In studies comparing telbivudine vs control, telbivudine showed improved maternal HBV DNA 
suppression at delivery (3 cohorts, RR 52.8 (95% CI, 10.7 - 261.8) I
2
=0%), at 4 weeks 
postpartum (2 cohorts, RR 102(95% CI, 14.4 - 722.8) I
2
=0%) and at 28 weeks postpartum (1 
cohort, RR 1.5 (95% CI, 1.2 - 1.8). When compared to control, pregnant women receiving 
telbivudine consistently had improved maternal ALT normalization at delivery (2 cohorts, RR 
1.5 (95% CI, 1.2 - 1.8) I
2
=0%), at 4 weeks postpartum (1 cohort, RR 1.6 (95% CI, 1.1 - 2.3) and 
at 28 weeks postpartum (1 cohort, RR 1.3(95% CI, 1.04 to 1.6). Telbivudine also significantly 
increased maternal HBeAg loss at delivery (2 cohorts, RR 1.7 (95% CI, 1.3 - 2.2) I
2
=0%), at 4 
weeks postpartum (1 cohort, RR 1.6 (95% CI, 1.2 - 2.2) and at 28 weeks postpartum (1 cohort, 
RR 1.7 (95% CI, 1.2 - 2.29). Tenofovir compared to control showed significant improvement in 
HBV DNA suppression at delivery (2 cohorts, RR 45.4(95% CI, 9.3 - 222.5) but not ALT 
normalization or HBeAg seroconversion. 
Compared to lamivudine, pregnant women treated with telbivudine had significantly greater 
HBV DNA suppression at delivery (1 cohort, RR 1.8 (95% CI, 1.3 to 2.6) but not HBeAg loss 
(RR 1.1 (95% CI, 0.1 to 21.5) or seroconversion (RR 0.6 (95% CI, 0.03 to 15.2).  
When comparing any antiviral therapy vs. control for maternal harms, no statistically significant 
difference was found in postpartum hemorrhage rate, CS rate and elevated creatine kinase rate. 
The quality of the evidence in maternal outcomes was very low due to the observational nature 
of the studies, imprecision and indirectness. Figures 7-9 show maternal outcomes reported at 
delivery in studies comparing lamivudine, telbivudine and tenofovir treatment vs control group 
respectively. Table 4 summarizes the quality of evidence (GRADE) for infant and maternal 
outcomes. 
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Publication bias:  
We were unable to evaluate publication bias due to small number of studies for each outcome.  
Discussion: 
For women who are or may become pregnant, consideration of the potential harms and benefits 
to the fetus as well as the mother complicate medication treatment decisions is important, such as 
administering antiviral therapy for CHB during pregnancy. Although the benefit for antiviral 
therapy is unproven for the many women of childbearing age who are in the immune tolerant 
phase of CHB, these women have the highest risk of MTCT. Thus characterizing the safety of 
these medications for the mother and fetus during pregnancy can help inform potential treatment 
choices for women of child-bearing age.  Even for women who are in the immune active phase 
of CHB infection antiviral treatment may be postponed until after completion of childbearing as 
long as they have compensated liver disease.    Additionally, post-delivery neonatal combined 
immunoprophylaxis successfully prevents HBV infection in approximately 90% of infants. Thus, 
prevention of MTCT of HBV does not necessarily mandate antiviral treatment during pregnancy 
for most women.  However, the current failure rate of post-exposure neonatal 
immunoprophylaxis against MTCT of HBV may be unacceptably high (~9%) in women with 
high levels of viremia (serum HBV DNA > 10
6
 copies/mL; ~2 x10
5
 IU/mL) (10).  
Among infants who received hepatitis B vaccine starting at birth, this meta-analysis found that 
antiviral therapy with lamivudine, telbivudine, or tenofovir in pregnant women with high levels 
of HBV DNA reduced MTCT rates, with over 70% reductions in the rates of infant HBsAg and 
HBV DNA positivity at 6-12 months post-partum.  In non-head-to-head trials, telbivudine 
showed higher rates of HBV DNA suppression, ALT normalization and HBeAg seroconversion 
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than lamivudine.  For tenofovir, there were insufficient controlled outcome data. No safety issues 
for maternal or fetal outcomes were identified in our meta-analysis of these studies.  Thus 
antiviral therapy in the third trimester for women who are HBeAg + with a HBV DNA level 
greater than 2x10
5 
IU/mL to prevent MTCT seems warranted (see the accompanying AASLD 
Hepatitis B Treatment Guidelines for details). 
Although lamivudine, telbivudine and tenofovir are licensed for CHB and HIV treatment, none 
of these drugs are approved for use in pregnancy.  Telbivudine and tenofovir are currently rated 
pregnancy category B, and lamivudine pregnancy category C, by the United States Food and 
Drug Administration (US FDA) based primarily on animal data with no clear evidence of harm 
in sparse human data.  However, the substantial experience in the use tenofovir and lamivudine 
in HIV- infected pregnant women to prevent HIV transmission has not identified any significant 
safety concerns for either mother or newborn(20). Recent data in women with HIV have reported 
lower bone mineral content in newborns exposed to tenofovir throughout pregnancy (53), but 
earlier data did not show any impact on early growth in infants exposed to tenofovir in utero 
(54), so the significance of this finding is unclear.  Additionally, initiating tenofovir, lamivudine, 
or telbivudine for CHB during pregnancy may be less worrisome because the antiviral agents are 
usually started in the late second or early third trimester in mothers with high HBV DNA levels 
to reduce maternal viremia and hence the risk of MTCT of HBV.  Concern remains over the 
propensity to develop viral resistance to lamivudine or telbivudine (55) if it is used throughout 
the pregnancy or postpartum, rather than restricted to the late second and third trimester. On the 
other hand, tenofovir has a high resistance barrier with no resistance identified to date after up to 
6 years of monotherapy for CHB (56). 
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The major limitation of this systematic review is the absence of studies warranting high 
confidence.  With a paucity of RCTs, most of the data are derived from cohort studies, which are 
subject to significant biases, especially selection bias.  Additionally, despite a report from the 
Antiviral Pregnancy Registry finding no increased risk of birth defects for lamivudine or 
tenofovir (26), data on fetal safety with antivirals remain limited, particularly for telbivudine. 
Recommendations for management of chronic HBV infection during pregnancy are provided in 
the updated AASLD guidelines (57). 
Conclusion: 
In pregnant women with chronic HBV infection, the oral antiviral therapies lamivudine, 
telbivudine, and tenofovir, lowers HBV DNA level as they do in non-pregnant women and 
reduce the rates of MTCT. These effects were demonstrated in women who are HBeAg positive 
with high viral loads (>10
6
 copies or ~2x10
5
 IU/mL).  The limited safety data suggest no 
increased risk of adverse maternal or fetal outcomes.  Larger scale RCTs of tenofovir are 
ongoing and these results are eagerly awaited. In the meantime, the use of these agents in women 
who are HBeAg positive and have HBV DNA > 10
6 
copies/mL (20,000 IU/mL) in the third 
trimester to prevent MTCT is recommended. 
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Figure 2: Forest plots of infant outcomes for RCTs comparing any antiviral therapy vs control at 
6-12 months follow up 
 
Figure 3: Forest plots of infant outcomes for RCTs comparing lamivudine vs control at 6-12 
months follow up 
 
Figure 4: Forest plots of infant outcomes for RCTs comparing telbuvidine vs control at 6-12 
months follow up 
 
Figure 5: Forest plots of infant outcomes for non-RCTs comparing tenofovir vs control at 6-12 
months follow up 
 
 
Figure 6: Forest plot of congenital malformation and prematurity rates reported for studies 
comparing any antiviral therapy vs control 
 
Figure 7: Forest plot of maternal outcomes for non-RCTs comparing lamivudine vs control at 
delivery 
 
Figure 8: Forest plot of maternal outcomes for non-RCTs studies comparing telbivudine vs 
control at delivery 
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Table 1: Characteristics of the included studies: 


























20-40 7.4 ± 0.8 NR 32-36 NR 
All  RCT 







8.6 ± 0.2 
0.4(0.1-5.3) 
xULN 




Control group 61 
25(20-
36) 








20-40 NR NR 28 4 
All  RCT 




20-40 7.5 ± 0.5 NR 28 4 
All RCT 





NR 6.8 ± 0.9 NR 28 4 
All RCT 
Control group 50 NR 
6.9 ± 1.7 
 





NR 7.2 ± 1.9 NR 28 4 
All RCT 





NR NR NR 28 4 
All RCT 





NR 8.0 ± 1.2 NR 28 4 
All RCT 





NR 8.7 ± 0.7 NR 28 4 
All RCT 





NR 7.7 ± 4.6 NR 28 4 
All RCT 










Lamivudine 51 28.4±7.1 6.9±0.4 39.7±26.4 28-30 4 







7.9 ± 0.8 28(22-36) 32 12 
All  Cohort study Lamivudine 52 28.0±5.3 7.7 ± 0.6 22(18-30) 32 4 





28.2±4.1 8.3 56(22-71) 18 - 27 4 
All  Retrospective study 









All  Cohort study 
Control group 92 26.4±3.2 7.9±0.6 42.2±0.4 NA NA 
Chen, Lamivudine 75 China NR 7.7±0.5 NR 24-32 4 All  Cohort study 






























Continued for variable 
duration after delivery All  Cohort study 











Continued for variable 





Control group 35 
27(21-
33) 









All  Cohort study 











All  Cohort study 
Control group 94 
26(20-
35) 





NR 8.3 ± 1.2 NR 28 4 
All RCT 




NR 6.9 ± 0.8 NR 28 4 
All RCT 





NR 7.2 ± 0.9 NR 28 4 
All RCT 





NR NR NR 28 4 
AllNR RCT 





NR 7.5 ± 0.6 NR 28 4 
All RCT 









trial. Control group 56 32.4±3.1 8.2±0.4  23.3±36.2 NA NA 
Yu, 
2014(51) 
Telbivudine  233 
China 
26.8±3.9 7.8 ± 0.8 57.6 ± 83.5 8-32 At delivery 
All  Cohort study 
Lamivudine  154 26.7±3.5 7.7 ± 0.7 56.3 ± 82.7 NA NA 
 



































Risk of bias 





Xu, 2009(27) Unclear 
Sequentially numbered drug 
containers of identical 
appearance 
Adequate blinding 
One arm of data 
missing for 
ethics 




Yang, 2008(28) Random number table 
Sequentially numbered 



















Zhang, 2010(30) Unclear Unclear Unclear Unclear None None Unclear 
Shi, 2009(31) Computer random number generator 
Sequentially numbered drug 




have no impact 















Shi, 2005(34) Random table Unclear 
Measurement not 









































Selection Comparability Outcome 
Representativeness of the 
exposed cohort 
Selection of the non-
exposed cohort 
Comparability of cohorts 
on the basis of the design 
or analysis. 
Assessment of outcome Was follow up long enough 
for outcomes to occur 
Adequacy of follow up of 
cohorts 
Zhang, 2014(36) Somewhat representative of 
the community or population 
Drawn from the same 
community as the exposed 
cohort 
Study controls for any 
additional factors 
Record linkage Yes Adequate 
Greenup, 2014(37) Somewhat representative of 
the community or population 
Drawn from the same 
community as the exposed 
cohort 
Study controls for any 
additional factors 
Record linkage Yes Adequate 
Celen, 2013(38) Somewhat representative of 
the community or population 
Drawn from the same 
community as the exposed 
cohort 
Study controls for most 
important factor 
Record linkage Yes Adequate 
Jiang, 2012(39) No description Drawn from the same 
community as the exposed 
cohort 
Study controls for most 
important factor 
No description Yes Adequate 
Chen, 2012(40) No description Drawn from the same 
community as the exposed 
cohort 
Study controls for most 
important factor 
No description No Unclear 
Yu, 2012(41) Somewhat representative of 
the community or population 
Drawn from the same 
community as the exposed 
cohort 
Study controls for most 
important factor 
Record linkage Yes Adequate 
Pan, 2012(42) Somewhat representative of 
the community or population 
Drawn from the same 
community as the exposed 
cohort 
Study controls for most 
important factor 
Record linkage Yes Adequate 
Han, 2012(43) No description Drawn from the same 
community as the exposed 
cohort 
Study controls for most 
important factor 
No description Unclear unclear 
Han, 2011(44) Somewhat representative of 
the community or population 
Drawn from the same 
community as the exposed 
cohort 
Study controls for most 
important factor 
Record linkage Yes Adequate 
Feng, 2007(45) No description No description No description No description No description No description 
Li, 2006(46) No description No description No description No description No description No description 
Han, 2005(47) No description No description No description No description No description No description 
Yao, 2011(48) No description No description No description No description No description No description 
Zhang, 2010(49) No description No description No description No description No description No description 
Chen, 2015(50) Somewhat representative of 
the community or population 
Drawn from the same 
community as the exposed 
cohort 
Study controls for any 
additional factors 
Record linkage Yes Adequate 
Yu, 2014(51) somewhat representative of 
the community or population 
Drawn from the same 
community as the exposed 
cohort 






















Supplemental table 1: Detailed Search Strategy: 
Ovid 
Database(s): Embase 1988 to 2014 Week 36, Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and 
Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, 
EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014  
Search Strategy: 
# Searches Results 
1 exp Hepatitis B/dt 26394 
2 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or "hepatitis type B").mp. 178415 
3 1 or 2 178415 
4 exp Antiviral Agents/ 915473 
5 exp antivirus agent/ 611278 
6 
("1-Deoxynojirimycin" or absouline or "abt 333" or "abt 450" or Acetylcysteine or aciclovir or 
"acyclouridine derivative" or Acyclovir or "adenine xyloside" or "adenosine dialdehyde" or afovirsen 
or "al 721" or alamifovir or alisporivir or "aln rsv 01" or "alvircept sudotox" or amantadine or 
amenamevir or amidapsone or amitivir or "ammonium trichloro dioxyethylene o o tellurate" or 
amsacrine or "ana 975" or "anti viral agent" or AntiRetroviral* or "Anti-Retroviral*" or antiretrovirus 
or antiviral* or "anti-viral*" or Aphidicolin or arasangivamycin or arbidol or arildone or astodrimer or 
asunaprevir or avarol or avarone or avridine or "azd 7295" or balapiravir or bavituximab or "behenyl 
alcohol" or benzimidavir or besifovir or boceprevir or bonaphthone or "Brefeldin A" or brincidofovir 
or Bromodeoxyuridine or bropirimine or buciclovir or carbocyclic or carbodine or carrageenan or 
cidofovir or ciluprevir or clevudine or "cpg 10101" or crofelemer or cyclaradine or "cyclosporin A" or 
cytarabine or daclatasvir or damavaricin or danoprevir or dasabuvir or deitiphorin or deleobuvir or 
denotivir or deoxyaristeromycin or Deoxyglucose or deoxypenciclovir or deoxyribavirin or desciclovir 
or detiviciclovir or "didemnin A" or "didemnin B" or Dideoxyadenosine or Dideoxynucleoside* or 
disoxaril or "distamycin 5" or "distamycin A" or Ditiocarb or droxinavir or edoxudine or elbasvir or 
"enisamium iodide" or enviroxime or epetirimod or eudistomin or exbivirumab or faldaprevir or 
famciclovir or favipiravir or felvizumab or fiacitabine or fialuridine or filibuvir or Filipin or florenal or 
"flucytosine arabinoside" or fomivirsen or foravirumab or fosarilate or foscarnet or fosdevirine or 
fucoidin or "gamma venin" or ganciclovir or "gene expression modulator" or grazoprevir or "gs 9256" 
or "guanine 7 oxide" or hypericin or "hypoxanthine arabinoside" or idoxuridine or "idoxuridine 
derivative" or "idx 184" or imexon or imiquimod or "Inosine Pranobex" or iododeoxycytidine or 
ipilimumab or isatoribine or "isis 13312" or "isis 14803" or laninamivir or larifan or ledipasvir or 
letermovir or levovirin or lexithromycin or libivirumab or litomeglovir or lomibuvir or mericitabine or 
merimepodib or Methisazone or methisoprinol or methylcytidine or metisazone or miravirsen or 
moroxydine or motavizumab or "mycophenolic acid" or "Myxovirus resistance protein" or "n 
bromoacetyldistamycin A" or narlaprevir or neceprevir or "neominophagen C" or nesbuvir or 
netivudine or netropsin or nivocasan or omaciclovir or ombitasvir or oseltamivir or palivizumab or 
penciclovir or "penciclovir triphosphate" or peramivir or "phosphonoacetic acid" or "Phosphonoacetic 
Acid" or pirazofurin or pirodavir or pleconaril or pocapavir or "pokeweed antivirus protein" or "Poly 
A-U" or "Poly I-C" or pritelivir or pseudohypericin or "pyran copolymer" or "Pyran Copolymer" or 
radavirsen or rafivirumab or "recombinant intercellular adhesion molecule 1" or regavirumab or 
resiquimod or ribavirin or "ribavirin derivative" or rifabutin or rimantadine or rintatolimod or riodoxol 
or rociclovir or rupintrivir or samatasvir or sangivamycin or "sangivamycin derivative" or 
"scopadulcic acid B" or setrobuvir or sevirumab or simeprevir or sofosbuvir or sorivudine or 
sovaprevir or streptovaricin or Streptovaricin or streptovirudin or suramin or suvizumab or synadenol 
or synguanol or taribavirin or tebrofen or tecovirimat or tegobuvir or telaprevir or telbivudine or 
"Tenuazonic Acid" or "thiarubrine A" or "thiophene A" or "thymine arabinoside" or tilorone or 
Tilorone or "tilorone derivative" or tiviciclovir or tomeglovir or torcitabine or trifluridine or 
tromantadine or tunicamycin or tuvirumab or umifenovir or "uracil arabinoside" or valaciclovir or 
valganciclovir or valomaciclovir or valopicitabine or valtorcitabine or vaniprevir or vapendavir or 
747307 
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vedroprevir or vidarabine or Vidarabine or viracine or "viral inhibitor*" or virantmycin or virostatic* 
or viroxime or virucidal* or virucide* or "virus repressor*" or virustatic* or xanthogenate or 
"xenazoic acid" or zanamivir or Zanamivir or zinviroxime).mp. 
4 or 5 or 6 1208899 
exp Interferons/ 453504 
exp interferon/ 453504 
0 
("cl 884" or cl884 or ifn or interferon* or interferone* or interferonogen* or interferron* or 
"interleukin 28A" or "interleukin 29" or "interleukin 6" or leif or peginterferon* or peginterferone* or 
peginterferonogen* or peginterferron*).mp. 
628658 
1 8 or 9 or 10 628758 
2 exp Pregnancy/ 1080989 
3 (pregnan* or gestation* or "child bearing" or childbearing).mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, kf, px, rx, ui, tx, ct] 1448492 
4 12 or 13 1463788 
5 3 and (7 or 11) and 14 1340 
6 exp evidence based medicine/ 721205 
7 exp meta analysis/ 134011 
8 exp Meta-Analysis as Topic/ 29510 
9 exp "systematic review"/ 79207 
0 exp Guideline/ or exp Practice Guideline/ 344377 
1 exp controlled study/ 4512490 
2 exp Randomized Controlled Trial/ 723249 
3 exp triple blind procedure/ 68 
4 exp Double-Blind Method/ 342895 
5 exp Single-Blind Method/ 51259 
6 exp latin square design/ 276 
7 exp Placebos/ 267995 
8 exp Placebo Effect/ 7231 
9 exp comparative study/ 2459742 
0 exp Cross-Sectional Studies/ 307288 
1 exp Cross-Over Studies/ 101407 
2 exp Cohort Studies/ 1680397 
3 exp longitudinal study/ 1065024 
4 exp retrospective study/ 864314 
5 exp prospective study/ 701082 
6 exp population research/ 68087 
7 exp observational study/ 65081 
8 exp clinical trial/ 1728711 
9 clinical study/ 53598 
0 exp Evaluation Studies/ 208013 
1 exp Evaluation Studies as Topic/ 1130031 
2 exp Twin Study/ 31182 
3 exp quantitative study/ 5818 
4 exp validation studies/ 113515 
5 exp experimental study/ 14612 
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6 exp quasi experimental study/ 2028 
7 exp field study/ 1531 
8 in vivo study/ 189705 
9 exp panel study/ 373 
0 exp Pilot Projects/ 171018 
1 exp pilot study/ 171018 
2 exp prevention study/ 2120 
3 exp replication study/ 949 
4 exp theoretical study/ 1368248 
5 exp Feasibility Studies/ 99507 
6 exp Models, Theoretical/ 1387826 
7 exp trend study/ 11365 
8 exp correlational study/ 11312 
9 exp case-control studies/ 784804 
0 exp confidence interval/ 122062 
1 exp regression analysis/ 570654 
2 exp proportional hazards model/ 94889 
3 exp multivariate analysis/ 343014 
4 "limit follow up studies to medline only. embase maps to follow up".ti. 0 
5 exp follow up studies/ 1343640 
6 exp case study/ 1738225 
7 "limit case study above to embase only. medline maps to case report".ti. 0 
8 odds ratio/ 383358 
9 "limit odds ratio above to embase. medline maps to risk".ti. 0 
0 
((evidence adj based) or (meta adj analys*) or (systematic* adj3 review*) or guideline* or (doubl* adj 
blind*) or (doubl* adj mask*) or (singl* adj blind*) or (singl* adj mask*) or (tripl* adj blind*) or 
(tripl* adj mask*) or (trebl* adj blind*) or (trebl* adj mask*) or "latin square" or placebo or random* 
or control* or multivariate or "comparative study" or "comparative survey" or "comparative analysis" 
or compar* or (intervention* adj2 study) or (intervention* adj2 trial) or "cross-sectional study" or 
"cross-sectional analys*" or "cross-sectional survey*" or "cross-sectional design*" or "prevalence 
study" or "prevalence analys*" or "prevalence survey*" or "disease frequency study" or "disease 
frequency analys*" or "disease frequency survey*" or crossover or "cross-over" or cohort* or 
"longitudinal study" or "longitudinal survey" or "longitudinal analysis" or longitudinal* or 
"retrospective study" or "retrospective survey" or "retrospective analysis" or retrospectiv* or 
"prospective study" or "prospective survey" or "prospective analysis" or prospectiv* or "population 
study" or "population survey" or "population analysis" or "concurrent study" or "concurrent survey" or 
"concurrent analysis" or "incidence study" or "incidence survey" or "incidence analysis" or "follow-up 
study" or "follow-up survey" or "follow-up analysis" or "observational study" or "observational 
survey" or "observational analysis" or "case study" or "case series" or "clinical series" or "case 
studies" or "clinical study" or "clinical trial" or "evaluation study" or "evaluation survey" or 
"evaluation analysis" or "twin study" or "twin survey" or "twin analysis" or "quantitative study" or 
"quantitative analys*" or "validation study" or "validation survey" or "validation analysis" or 
"experimental study" or "experimental analysis " or "quasi experimental study" or "quasi experimental 
analysis" or "quasiexperimental study" or "quasiexperimental analysis" or "field study" or "field 
survey" or "field analysis" or "in vivo study" or "in vivo analysis" or "panel study" or "panel survey" 
or "panel analysis" or "prevention study" or "prevention survey" or "prevention analysis" or 
"replication study" or "replication analysis " or "theoretical study" or "theoretical analysis " or 
"feasibility study" or "feasibility analysis " or "trend study" or "trend survey" or "trend analysis" or 
(correlation* adj2 study) or (correlation* adj2 analys*) or "case control study" or "case base study" or 
22128887 
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"case referrent study" or "case referent study" or "case compeer study" or "case comparison study" or 
study or trial or pilot or "odds ratio" or "confidence interval" or "regression analysis" or "hazards 
model" or "change analysis").mp. 
1 from 65 keep 793339-1301733 508395 
2 from 66 keep 1-25622 25622 
3 from 68 keep 1-318765 318765 
4 or/16-63 12606394 
5 or/70-74 23255184 
6 15 and 75 934 
7 from 15 keep 962-1300 339 
8 
limit 77 to (clinical trial, all or clinical trial, phase i or clinical trial, phase ii or clinical trial, phase iii 
or clinical trial, phase iv or clinical trial or comparative study or controlled clinical trial or evaluation 
studies or guideline or meta analysis or multicenter study or observational study or practice guideline 
or pragmatic clinical trial or randomized controlled trial or systematic reviews or twin study or 
validation studies) [Limit not valid in Embase,CCTR,CDSR; records were retained] 
83 
9 76 or 78 934 
0 
limit 79 to (book or book series or editorial or erratum or letter or note or addresses or autobiography 
or bibliography or biography or comment or dictionary or directory or interactive tutorial or interview 
or lectures or legal cases or legislation or news or newspaper article or overall or patient education 
handout or periodical index or portraits or published erratum or video-audio media or webcasts) [Limit 
not valid in Embase,Ovid MEDLINE(R),Ovid MEDLINE(R) In-Process,CCTR,CDSR; records were 
retained] 
41 
1 79 not 80 893 
2 from 15 keep 1301-1340 40 
3 81 or 82 916 
4 83 not (exp animals/ not exp humans/) 885 
5 from 83 keep 896-916 21 
6 84 or 85 906 
7 remove duplicates from 86 735 
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1 TITLE-ABS-KEY("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 
"hepatitis type B") 
2 TITLE-ABS-KEY("1-Deoxynojirimycin" OR absouline OR "abt 333" OR "abt 450" OR 
Acetylcysteine OR aciclovir OR "acyclouridine derivative" OR Acyclovir OR "adenine xyloside" OR 
"adenosine dialdehyde" OR afovirsen OR "al 721" OR alamifovir OR alisporivir OR "aln rsv 01" OR 
"alvircept sudotox" OR amantadine OR amenamevir OR amidapsone OR amitivir OR "ammonium 
trichloro dioxyethylene o o tellurate" OR amsacrine OR "ana 975" OR "anti viral agent" OR 
AntiRetroviral* OR "Anti-Retroviral*" OR antiretrovirus OR antiviral* OR "anti-viral*" OR 
Aphidicolin OR arasangivamycin OR arbidol OR arildone OR astodrimer OR asunaprevir OR avarol 
OR avarone OR avridine OR "azd 7295" OR balapiravir OR bavituximab OR "behenyl alcohol" OR 
benzimidavir OR besifovir OR boceprevir OR bonaphthone OR "Brefeldin A" OR brincidofovir OR 
Bromodeoxyuridine OR bropirimine OR buciclovir OR carbocyclic OR carbodine OR carrageenan OR 
cidofovir OR ciluprevir OR clevudine OR "cpg 10101" OR crofelemer OR cyclaradine OR 
"cyclosporin A" OR cytarabine OR daclatasvir OR damavaricin OR danoprevir OR dasabuvir OR 
deitiphorin OR deleobuvir OR denotivir OR deoxyaristeromycin OR Deoxyglucose OR 
deoxypenciclovir OR deoxyribavirin OR desciclovir OR detiviciclovir OR "didemnin A" OR 
"didemnin B" OR Dideoxyadenosine OR Dideoxynucleoside* OR disoxaril OR "distamycin 5" OR 
"distamycin A" OR Ditiocarb OR droxinavir OR edoxudine OR elbasvir OR "enisamium iodide" OR 
enviroxime OR epetirimod OR eudistomin OR exbivirumab OR faldaprevir OR famciclovir OR 
favipiravir OR felvizumab OR fiacitabine OR fialuridine OR filibuvir OR Filipin OR florenal OR 
"flucytosine arabinoside" OR fomivirsen OR foravirumab OR fosarilate OR foscarnet OR fosdevirine 
OR fucoidin OR "gamma venin" OR ganciclovir OR "gene expression modulator" OR grazoprevir OR 
"gs 9256" OR "guanine 7 oxide" OR hypericin OR "hypoxanthine arabinoside" OR idoxuridine OR 
"idoxuridine derivative" OR "idx 184" OR imexon OR imiquimod OR "Inosine Pranobex" OR 
iododeoxycytidine OR ipilimumab OR isatoribine OR "isis 13312" OR "isis 14803" OR laninamivir 
OR larifan OR ledipasvir OR letermovir OR levovirin OR lexithromycin OR libivirumab OR 
litomeglovir OR lomibuvir OR mericitabine OR merimepodib OR Methisazone OR methisoprinol OR 
methylcytidine OR metisazone OR miravirsen OR moroxydine OR motavizumab OR "mycophenolic 
acid" OR "Myxovirus resistance protein" OR "n bromoacetyldistamycin A" OR narlaprevir OR 
neceprevir OR "neominophagen C" OR nesbuvir OR netivudine OR netropsin OR nivocasan OR 
omaciclovir OR ombitasvir OR oseltamivir OR palivizumab OR penciclovir OR "penciclovir 
triphosphate" OR peramivir OR "phosphonoacetic acid" OR "Phosphonoacetic Acid" OR pirazofurin 
OR pirodavir OR pleconaril OR pocapavir OR "pokeweed antivirus protein" OR "Poly A-U" OR "Poly 
I-C" OR pritelivir OR pseudohypericin OR "pyran copolymer" OR "Pyran Copolymer" OR radavirsen 
OR rafivirumab OR "recombinant intercellular adhesion molecule 1" OR regavirumab OR resiquimod 
OR ribavirin OR "ribavirin derivative" OR rifabutin OR rimantadine OR rintatolimod OR riodoxol OR 
rociclovir OR rupintrivir OR samatasvir OR sangivamycin OR "sangivamycin derivative" OR 
"scopadulcic acid B" OR setrobuvir OR sevirumab OR simeprevir OR sofosbuvir OR sorivudine OR 
sovaprevir OR streptovaricin OR Streptovaricin OR streptovirudin OR suramin OR suvizumab OR 
synadenol OR synguanol OR taribavirin OR tebrofen OR tecovirimat OR tegobuvir OR telaprevir OR 
telbivudine OR "Tenuazonic Acid" OR "thiarubrine A" OR "thiophene A" OR "thymine arabinoside" 
OR tilorone OR Tilorone OR "tilorone derivative" OR tiviciclovir OR tomeglovir OR torcitabine OR 
trifluridine OR tromantadine OR tunicamycin OR tuvirumab OR umifenovir OR "uracil arabinoside" 
OR valaciclovir OR valganciclovir OR valomaciclovir OR valopicitabine OR valtorcitabine OR 
vaniprevir OR vapendavir OR vedroprevir OR vidarabine OR Vidarabine OR viracine OR "viral 
inhibitor*" OR virantmycin OR virostatic* OR viroxime OR virucidal* OR virucide* OR "virus 
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repressor*" OR virustatic* OR xanthogenate OR "xenazoic acid" OR zanamivir OR Zanamivir OR 
zinviroxime) 
3 TITLE-ABS-KEY("cl 884" OR cl884 OR ifn OR interferon* OR interferone* OR interferonogen* OR 
interferron* OR "interleukin 28A" OR "interleukin 29" OR "interleukin 6" OR leif OR peginterferon* 
OR peginterferone* OR peginterferonogen* OR peginterferron*) 
4 TITLE-ABS-KEY(pregnan* or gestation* or "child bearing" or childbearing) 
5 TITLE-ABS-KEY((evidence W/1 based) OR (meta W/1 analys*) OR (systematic* W/3 review*) OR 
(guideline*) OR (doubl* W/1 blind*) OR (doubl* W/1 mask*) OR (singl* W/1 blind*) OR (singl* 
W/1 mask*) OR (tripl* W/1 blind*) OR (tripl* W/1 mask*) OR (trebl* W/1 blind*) OR (trebl* W/1 
mask*) OR "latin square" OR placebo OR random* OR control* OR multivariate OR "comparative 
study" OR "comparative survey" OR "comparative analysis" OR compar* OR (intervention* W/2 
study) OR (intervention* W/2 trial) OR "cross-sectional study" OR "cross-sectional analys*" OR 
"cross-sectional survey*" OR "cross-sectional design*" OR "prevalence study" OR "prevalence 
analys*" OR "prevalence survey*" OR "disease frequency study" OR "disease frequency analys*" OR 
"disease frequency survey*" OR crossover OR "cross-over" OR cohort* OR "longitudinal study" OR 
"longitudinal survey" OR "longitudinal analysis" OR longitudinal* OR "retrospective study" OR 
"retrospective survey" OR "retrospective analysis" OR retrospectiv* OR "prospective study" OR 
"prospective survey" OR "prospective analysis" OR prospectiv* OR "population study" OR 
"population survey" OR "population analysis" OR "concurrent study" OR "concurrent survey" OR 
"concurrent analysis" OR "incidence study" OR "incidence survey" OR "incidence analysis" OR 
"follow-up study" OR "follow-up survey" OR "follow-up analysis" OR "observational study" OR 
"observational survey" OR "observational analysis" OR "case study" OR "case series" OR "clinical 
series" OR "case studies" OR "clinical study" OR "clinical trial" OR "evaluation study" OR 
"evaluation survey" OR "evaluation analysis" OR "twin study" OR "twin survey" OR "twin analysis" 
OR "quantitative study" OR "quantitative analys*" OR "validation study" OR "validation survey" OR 
"validation analysis" OR "experimental study" OR "experimental analysis " Or "quasi experimental 
study" OR "quasi experimental analysis" OR "quasiexperimental study" OR "quasiexperimental 
analysis" OR "field study" OR "field survey" OR "field analysis" OR "in vivo study" OR "in vivo 
analysis" OR "panel study" OR "panel survey" OR "panel analysis" OR "prevention study" OR 
"prevention survey" OR "prevention analysis" OR "replication study" OR "replication analysis " OR 
"theoretical study" OR "theoretical analysis " OR "feasibility study" OR "feasibility analysis " OR 
"trend study" OR "trend survey" OR "trend analysis" OR (correlation* W/2 study) OR (correlation* 
W/2 analys*) OR "case control study" OR "case base study" OR "case referrent study" OR "case 
referent study" OR "case compeer study" OR "case comparison study" OR study OR trial OR pilot OR 
"odds ratio" OR "confidence interval" OR "regression analysis" OR "hazards model" OR "change 
analysis") 
6 1 and 2 and 3 and 4 and 5 
7 DOCTYPE(le) OR DOCTYPE(ed) OR DOCTYPE(bk) OR DOCTYPE(er) OR DOCTYPE(no) OR 
DOCTYPE(sh) 
8 6 and not 7 
9 PMID(0*) OR PMID(1*) OR PMID(2*) OR PMID(3*) OR PMID(4*) OR PMID(5*) OR PMID(6*) 
OR PMID(7*) OR PMID(8*) OR PMID(9*) 
10 8 and not 9 
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Supplemental Table 2: Quality of evidence summary: 
Intervention Outcome (Follow up) 
No. of participants  
(Study design) 






Any antiviral vs 
none 







(0.16 to 0.44) 








(0.12 to 0.38) 







(0.20 to 0.49) 








(0.17 to 0.84) 















(0.35 to 1.53) 
Lamivudine vs 
None 








(0.15 to 0.56) 









(0.03 to 0.45) 








(0.21 to 0.56) 
Infant HBV DNA positivity 
(6-12 m) 
90 












Means differences  
0.012 
(-0.75 to 0.47) 















(0.35 to 1.65) 
Telbivudine vs 
control 








(0.10 to 0.52) 









(0.01 to 0.49) 
















Means difference  
-0.009 








(0.01 to 6.76) 











































































Infant HBsAg seropositivity 
(6-12 m) 
219 




(0.07 to 0.70) 







(0.01 to 28.8) 




(0.05 to 25.21) 
Telbivudine vs 
lamivudine 








(0.65 to 1.48) 




(0.55 to 7.21) 
Tenofovir vs 
Lamivudine 
Infant HBsAg seropositivity 
(at birth) 
87 




(0.12 to 70.08) 




(0.04 to 4.9) 
















(3.54 to 921.41) 
Maternal HBV DNA 
suppression 
















(0.74 to 2.31) 






(0.7 to 1.31) 







(0.78 to 1.26) 






(0.71 to 1.3) 







(0.89 to 1.31) 
Elevated Creatinine kinase rate 
185 




(0.12 to 72.03) 
Telbivudine vs 
control 









(10.66 to 261.82) 
Maternal HBN DNA 
Suppression 







(14.4 to 722.83) 
Maternal HBN DNA 
Suppression 
(28 weeks postpartum) 
88 









3 RR 1.46 









































































studies) VERY LOW (1.18 to 1.8) 
ALT normalization 
(4 weeks postpartum) 
88 




(1.1 to 2.31) 
ALT normalization 
(28 weeks postpartum) 
88 




(1.04 to 1.62) 








(1.25 to 2.24) 
Maternal HBeAg loss 
(4 weeks postpartum) 
88 




(1.24 to 2.15) 
Maternal HBeAg loss 
(28 weeks postpartum) 
88 














(0.31 to 27.58) 
Maternal HBeAg 
seroconversion 
(4 weeks postpartum) 
88 




(0.16 to 67.42) 
Maternal HBeAg 
seroconversion 
(28 weeks postpartum) 
88 




(0.67 to 190.29) 







(0.94 to 1.45) 
Postpartum hemorrhage 
308 




(0.64 to 1.25) 
Elevated Creatinine kinase rate 
637 




(0.69 to 236.44) 
Tenofovir vs 
control 



























(0.89 to 1.88) 
Cesarean section rate 
78 




(0.41 to 7.21) 
Postpartum hemorrhage 
78 




(0.15 to 2.19) 




(0.15 to 79.47) 
Telbivudine vs 
Lamivudine 








(1.28 to 2.61) 
Maternal HBV DNA 
suppression 303 ⨁◯◯◯
34 RR 1.24 









































































(4 weeks postpartum) (1 observational study) VERY LOW (0.78 to 1.97) 
Maternal HBeAg loss 
(at delivery) 
310 













(0.03 to 15.21) 
Cesarean section rate 
387 




(0.86 to 1.3) 
Elevated Creatinine kinase rate 
318 












(0.36 to 1.62) 
Footnotes: 
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